Industry Experts

Tom Lilly Stephen is Co-founder and President of Modunai Therapeutics, a stealth-stage biotech developing next-generation antibody therapeutics for immune-resistant solid tumors and autoimmune diseases. He is an immunologist and translational scientist with extensive experience across immuno-oncology, immune tolerance, and antibody drug development, spanning monoclonal antibodies, bispecifics, and ADC platforms. Previously, he held scientific leadership roles in biotech and pharma, driving target discovery through early clinical translation. Dr. Stephen is particularly interested in mechanism-driven target selection and tumor microenvironment reprogramming strategies to overcome therapeutic resistance in immune-cold cancers.